Cirmtuzumab

Cirmtuzumab (also UC-961) is an anti-ROR1 humanised monoclonal antibody.[1][2]

Cirmtuzumab
Monoclonal antibody
Type?
SourceHumanized
TargetROR1
Clinical data
Other namesUC-961
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

It is an experimental drug in early-stage clinical trials for various cancers including chronic lymphocytic leukemia (CLL).[3][4]

References

  1. Choi MY, Widhopf GF, Castro J, Li H, Kidwell RL, Zhang SC, et al. (2015). "Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts". Blood. 126 (23): 1736. doi:10.1182/blood.V126.23.1736.1736.
  2. "Researchers to test novel drug combination against toughest breast cancers". Medical Express. 2018-08-27.
  3. Clinical trial number NCT03420183 for "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies" at ClinicalTrials.gov
  4. "1st Mantle Cell Lymphoma Patient Dosed in Phase 1/2 Trial Testing Cirmtuzumab-Imbruvica Combo". Lymphoma News Today. 2018-05-18.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.